NHIA Sterile Compounding Designated Person Certificate Program

The NHIA Sterile Compounding Designated Person Certificate Program prepares participants with the essential knowledge and practical skills needed to fulfill the responsibilities of a Designated Person as outlined in USP Chapter <797>. Across six targeted units, learners develop competency in environmental controls, SOP oversight, inspection preparedness, cleanroom certification evaluation, documentation excellence, and the creation and management of competency processes. Each session offers actionable guidance to support compliance with USP <797>, strengthen facility oversight, and enhance sterility assurance within compounding operations. After completing the program, participants earn a certificate of completion, demonstrating their commitment to effective sterile compounding management and ongoing quality improvement.

  • Unit 1: State of Control: Environmental Practices for Sterile Compounding  1.00 CE
  • Unit 2: Standard Operating Procedures (SOPs): The Blueprint for Safety and Excellence  0.75 CE
  • Unit 3: Inspection Ready: Excelling in Sterile Compounding Compliance  1.00 CE
  • Unit 4: Reading Between the Lines: How to Interpret and Verify Your Cleanroom Certification Report  1.25 CE
  • Unit 5: Documenting Excellence: Mastering Practices for Compliance and Clarity  0.75 CE
  • Unit 6: Competency Counts: Creating and Managing Competency Processes  0.75 CE

NHIA General CE Information

 

Search by Category
Search by Format
Sort By
Search by Keyword
  • Contains 3 Component(s), Includes Credits

    Participants will gain a comprehensive understanding of environmental control requirements within the cleanroom suite and learn how to select the proper materials and cleaning agents to maintain a controlled environment.

    Participants will gain a comprehensive understanding of environmental control requirements within the cleanroom suite and learn how to select the proper materials and cleaning agents to maintain a controlled environment. The course will also address best practices for investigating and remediating environmental excursions, ensuring that issues are resolved effectively and sustainably. Through structured guidance and practical application, learners will strengthen their ability to oversee competency processes with confidence. By the conclusion of the session, attendees will be prepared to uphold the rigorous standards essential to safe, compliant, and high-quality sterile compounding.

    Learning Objectives:

    1. Describe the specific environmental control requirements in the cleanroom suite.
    2. Select appropriate materials and cleaning agents for use in the cleanroom suite.
    3. Demonstrate correct hand hygiene, garbing, and material/personnel movement techniques to minimize contamination risk.
    4. Investigate environmental monitoring excursions, determine root causes, and implement/document effective corrective and preventative actions.

    NHIA General CE Information

    Devonne Moore

    Director of Clinical Quality

    KabaFusion

    Devonne Moore is the Director of Clinical Quality at KabaFusion. She earned her PharmD from Massachusetts College of Pharmacy and Health Sciences in 2014 after working in compounding pharmacy since 2009. Devonne has worked in both 503A and 503B facilities focusing on formulations. In her current role she works with team members across the country on cleanroom operations as well as inspection preparation and remediation.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Devonne Moore has no relevant financial relationships with ineligible companies to disclose.

  • Contains 3 Component(s), Includes Credits

    The session will focus on the critical role the designated person plays in ensuring that Standard Operating Procedures (SOPs) are both appropriate and effectively implemented within sterile compounding environments.

    The session will focus on the critical role the designated person plays in ensuring that Standard Operating Procedures (SOPs) are both appropriate and effectively implemented within sterile compounding environments. Participants will explore the importance of reviewing SOPs upon development and at least annually to confirm alignment with current practices. The session will also emphasize best practices for documenting revisions and communicating changes to all affected personnel. By the conclusion, learners will have a clear understanding of their responsibilities in managing and maintaining SOPs to promote safety, compliance, and excellence in sterile compounding operations.

    Learning Objectives:

    1. Specify when an SOP is required accorrding to USP <797>.
    2. Describe how the designated person is involved in SOP development and oversight.
    3. Develop examples of SOPs that are effective and meet regulatory requirements. 
    4. Established processes to review SOPs to ensure they reflect current practices and regulatory requirements. 

    Barbara Petroff, MS, RPh, FASHP, BCSCP, FNHIA, CAC, CSPP, IgCP

    Principal

    Shawler Petroff LLC

    Barbara Petroff is a graduate of Ohio State University College of Pharmacy. She completed a Master's Degree in Administration at Central Michigan University. After starting her career in research in Product Development specializing in sterile products she worked for several years in hospital pharmacy before turning to home infusion where she has been for over 30 years. In addition she was a surveyor for the ACHC for 23 years, taught Healthcare Management at University of Phoenix, was adjunct faculty for five schools of pharmacy and currently teaches a pharmacy technician training class. She has been a member of ASHP for many years serving on several committees. She was on the Executive Committee for the Section of Ambulatory Care Practitioners and served as the Chair of the Home Infusion Section Advisory Group.  She has been a member of NHIA and currently serves as the chair of the Sterile Compounding Practice Committee.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Barbara Petroff has no relevant financial relationships with ineligible companies to disclose.

  • Contains 3 Component(s), Includes Credits

    Participants will explore the roles of key regulatory agencies and healthcare accreditation organizations involved in pharmacy inspections and survey visits.

    Participants will explore the roles of key regulatory agencies and healthcare accreditation organizations involved in pharmacy inspections and survey visits. The course will provide practical guidance on appointing a designated person, preparing staff for inspections, and responding effectively to deficiencies cited in inspection reports. By the end of the session, attendees will have a clear understanding of how to establish and manage competency processes that ensure compliance with USP <797> standards and support excellence in sterile compounding practice.

    Learning Objectives:

    1. Describe the regulatory agencies and accreditation organizations that conduct inspections and surveys.
    2. Explain the role a designated person plays in preparing staff for inspection day.
    3. Identify who should draft and submit the official response to deficiencies cited in inspection reports.
    4. Develop a practical inspection-readiness plan to sustain continuous compliance. 

    NHIA General CE Information

    Zoe Glaras, PharmD, BCSCP

    Pharmacy Manager, Sterile Compounding Quality & Compliance

    Yale New Haven Health

    Zoe Glaras attended the University of Connecticut School of Pharmacy where she graduated with her Doctor of Pharmacy. She spent her first decade of sterile compounding in the home infusion industry as an IV Pharmacist eventually advancing to Pharmacy Manager. Her passion for compliance led her to the CT Department of Consumer Protections Drug Control Division where she was a Drug Control Agent responsible for monitoring drugs, cosmetics, and device distribution systems for compliance with State and Federal laws and regulations. Zoe is currently the Pharmacy Manager of Quality and Compliance for the Yale New Haven Health Smilow Oncology Ambulatory sites where she manages the system's Sterile Compounding Quality and Compliance team and provides regulatory support on USP <797> and <800> to the the Smilow Oncology Ambulatory sites.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Zoe Glaras has no relevant financial relationships with ineligible companies to disclose.

  • Contains 3 Component(s), Includes Credits

    Participants will learn how to review and interpret cleanroom certification reports to verify compliance with USP standards.

    Participants will learn how to review and interpret cleanroom certification reports to verify compliance with USP <797> standards. Key topics include identifying and evaluating critical report data, documenting personnel presence during testing, and confirming certifier training and competency. The course will also emphasize the importance of signing off on certification reports and ensuring all requirements are met. By the conclusion, attendees will be equipped with the knowledge and skills needed to confidently oversee cleanroom certification processes and maintain compliance in sterile compounding operations.

    Learning Objective:

    1. Describe the responsibilities of the designated person, including the need to sign off on the report. 
    2. Ensure certification records for the cleanroom suite meets the requirements of USP <797>.
    3. Identify where to find and interpret information included on a certification report.
    4. Utilize a checklist or structured tool to consistently document, verify, and sign off on certification reports.

    NHIA General CE Information

    Gene Decaminada, RPh, BSPharm, FNHIA

    Pharmacy Manager Home Infusion

    Yale New Haven Health

    Gene Decaminada is currently the Pharmacy Manager for the Home Infusion Program at Yale New Haven Health Services (YNHHS). NHIA Fellowship Award (2021);  CPA mentor (2021, 2022) YNHHS Mentor (2022); NHIA Peer Review Member (2021); CPA Professional Pharmacy Performance Award (2021); BPS Sterile Compounding Council Member (term concluded 12/31/21); former NHIA National Standards and Sterile Compounding Education Committee member; PTCB Certificate Program instructor CT Community College (2021); CPA Sterile Compounding Conference Committee member; NHIA Sterile Compounding Practice Committee (SCPC) member; Vizient Home Infusion subcommittee member; and a selected member of the Institute for Excellence at YNHHS Lean-In Class of 2022. 

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Gene Decaminada has no relevant financial relationships with ineligible companies to disclose.

    L Rad Dillon RPh

    Founder

    Coalition for Compounding Excellence

    Rad Dillon graduated from the University of Texas College of Pharmacy in 1981, and shortly thereafter entered the new home infusion industry, working for numerous national and regional providers in various managerial and corporate leadership roles. After ten years as a contract and full-time surveyor for ACHC, he has returned to private consulting. He recently founded the Coalition for Compounding Excellence (CCE), an accrediting organization for 503A compounding pharmacies, whose goal is to provide cost-effective, high-value accreditation services to these pharmacies. He is also a consultant for Gates Healthcare Associated (GHA) and the National Coalition for Drug Quality & Security (NCDQS). Areas of expertise include quality management, sterile compounding facilities and processes, clinical documentation, and hazardous drug handling.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    L Rad Dillon has no relevant financial relationships with ineligible companies to disclose.

  • Contains 3 Component(s), Includes Credits

    Participants will learn how to describe and apply best practices for documentation to ensure clarity, accuracy, and regulatory compliance.

    Participants will learn how to describe and apply best practices for documentation to ensure clarity, accuracy, and regulatory compliance. The course will highlight required documentation for sterile compounding, including personnel training records, competency assessments, and equipment documentation. Attendees will also explore strategies for maintaining documents that meet legal and regulatory requirements while protecting their integrity and accessibility. By the conclusion of the session, learners will be prepared to manage documentation processes effectively to support safe, compliant, and high-quality compounding operations.

    Learning Objectives:

    1. Identify key USP <797> documentation requirements for compounded sterile preparations.
    2. Apply proper techniques for correcting documentation errors while maintaining traceability.
    3. Design compliant systems for document retention, retrieval, and accessibility.
    4. Document staff competencies, training, and qualifications accurately and completely.

    NHIA General CE Information

    Jacob Deitsch, PharmD, BCPS, BCSCP, HDDP, IgCP

    Director of Pharmacy Education and Programs

    National Home Infusion Association

    Jacob Deitsch, PharmD, BCPS, BCSCP, HDDP, IgCP the Director of Pharmacy Education and Programs with the National Home Infusion Association (NHIA). Deitsch has ten years of infusion pharmacy experience with six years in the home infusion industry. At NHIA, Deitsch is responsible for oversight and participation in multidisciplinary clinical education planning, development, and implementation. Deitsch holds a Doctor of Pharmacy degree from the University of Toledo and holds certifications as a BCPS, BCSCP, HDDP and IgCP.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

     Jacob Deitsch has no relevant financial relationships with ineligible companies to disclose.

  • Contains 4 Component(s), Includes Credits

    By the end of the session, learners will be equipped to sustain high levels of sterility assurance and process reliability within their facilities.

    Participants will learn to clearly differentiate between training and competency, recognizing the unique role each plays in sterile compounding practices. The course will emphasize critical thinking in the design and management of competency processes that align with organizational needs. Attendees will also examine the importance of regularly updating content and procedures to remain compliant with evolving standards. By the end of the session, learners will be equipped to sustain high levels of sterility assurance and process reliability within their facilities.

    Learning Objectives:

    1. Understand the fundamental differences between training processes and competency assessment in sterile compounding environments.
    2. Learn and implement critical thinking skills necessary to create and manage effective processes for sterile compounding competencies.
    3. Recognize the importance of frequent content and process updates to maintain compliance and ensure patient safety.
    4. Communicate standard operating procedure (SOP) changes, and document everything clearly and transparently.

    NHIA General CE Information

    Samantha Tricarico, CPhT, CSPT

    Consultant

    Consultant

    Samantha Tricarico, CPhT, CSPT, has worked as a pharmacy technician for over 25 years. Her passion for aseptic technique and sterile compounding has helped her thrive in hands-on training and the creation of educational content. She feels fortunate to have provided home infusion training to pharmacy colleagues across the country. She is a proud member of the Sterile Compounding Practice Committee and Sterile Compounding Clinic for NHIA where she continues to share and build her knowledge. As a strong advocate for technicians, she continually supports efforts for technician career advancement, education opportunities, involvement, and recognition throughout the industry.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Samantha Tricarico has no relevant financial relationships with ineligible companies to disclose.

    Daniel Kyes, CPhT, CSPT, BCSCPT, FNHIA

    Healthcare Compliance Business Analyst

    California Specialty Pharmacy

    Dan Kyes, Healthcare Compliance Business Analyst for California Specialty Pharmacy.  Focus on USP 797/800, The Joint Commission Accreditation, training, continuous quality improvement.  Within my organization I help to create and implement SOPs, and training programs. I have my CPht, CSPT, and BCSCPT certifications and am licensed as a pharmacy technician in multiple states.  Member of NHIA Sterile Compounding Practice Committee and Faculty with the Sterile Compounding Clinic.  I am also a member for the 2024 class of NHIA Fellows.

    NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy. 

    Dan Kyes has no relevant financial relationships with ineligible companies to disclose.